Percutaneous assist devices in acute myocardial infarction with cardiogenic shock: Review, meta-analysis

Table 3 Benefit - harm observed in the experimental group and result of Trial Sequential Analysis

Groups			Mortality rate (%)		RRR	Effect of experimental support				Trial Sequential Analysis
Experimental	Control	Experimental	Control	NNT	NNH	Harm1	Benefit1	Required information size	Results
Inhospital mortality
IABP2	vs	Medical therapy2	45.99	40.62	-13.22		18	5.37		2174	Conclusive
PLVADs	vs	IABP	55.93	47.71	-17.23		12	8.22		1161	Inconclusive
ECMO + IABP	vs	IABP	36.36	60.53	39.92	5			24.16	150	Conclusive
ECMO + IABP2	vs	ECMO2	61.29	66.67	8.06	19			5.38	Not calculable	Inconclusive
Late mortality
IABP	vs	Medical therapy	52.02	39.32	-32.28		7	12.70		5984	Futility
IABP2	vs	Medical therapy2	52.08	37.68	-38.22		6	14.40		168	Conclusive

¹Number of patients out of 100;

²Comparison after sensitivity analysis.